Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.

MLA

Ashraf, Shoaib, et al. “Anti-COVID Property of Subcutaneous Ivermectin in Synergy with Zinc among Midlife Moderately Symptomatic Patients: A Structured Summary of a Study Protocol for a Randomised Controlled Trial.” Trials, vol. 22, no. 1, Sept. 2021, p. 591. EBSCOhost, https://doi.org/10.1186/s13063-021-05487-z.

APA

Ashraf, S., Ashraf, S., Farooq, I., Ashraf, S., Ashraf, M., Imran, M. A., Kalsoom, L., Akmal, R., Ghufran, M., Rafique, S., Akram, M. K., Habib, Z., Siddiqui, U. N., Ahmad, A., Arshad, S., Virk, M. A. R., Gul, M., Awais, A. B., Hassan, M., … Izhar, M. (2021). Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial. Trials, 22(1), 591. https://doi.org/10.1186/s13063-021-05487-z

Chicago

Ashraf, Shoaib, Sohaib Ashraf, Iqra Farooq, Sidra Ashraf, Moneeb Ashraf, Muhammad Ahmad Imran, Larab Kalsoom, et al. 2021. “Anti-COVID Property of Subcutaneous Ivermectin in Synergy with Zinc among Midlife Moderately Symptomatic Patients: A Structured Summary of a Study Protocol for a Randomised Controlled Trial.” Trials 22 (1): 591. doi:10.1186/s13063-021-05487-z.